Fortrea Holdings (FTRE) Income from Continuing Operations (2022 - 2026)
Fortrea Holdings (FTRE) reported Income from Continuing Operations of 23600000.0 for Q1 2026, up 95.81% on a YoY basis from 12052658.32 in Q1 2025, and up 27.38% quarter-over-quarter from 32500000.0 in Q4 2025.
Fortrea Holdings (FTRE) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported Income from Continuing Operations for 5 years, with the latest figure at 23600000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 95.81% year-over-year to 23600000.0; the trailing twelve-month figure through Mar 2026 stood at 446900000.0 (up 40.78% YoY), and the FY2025 full-year result was 986200000.0, down 263.24% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 23600000.0, up from 32500000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 66400000.0 in Q2 2022, with the low at 562900000.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 74975000.0 across 5 years, with a median of 21050000.0 in 2024.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations plunged 1097.5% — and 2026, when it jumped 95.81%.
- Fortrea Holdings' Income from Continuing Operations stood at 13600000.0 in 2022, then slumped by 257.35% to 48600000.0 in 2023, then sank by 52.06% to 73900000.0 in 2024, then soared by 56.02% to 32500000.0 in 2025, then gained by 27.38% to 23600000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 23600000.0 (Q1 2026), 32500000.0 (Q4 2025), and 15900000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | -23.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.60 Mn |
| Dec 31, 2025 | -32.50 Mn |
| Sep 30, 2025 | -15.90 Mn |
| Jun 30, 2025 | -374.90 Mn |
| Mar 31, 2025 | -562.90 Mn |
| Dec 31, 2024 | -73.90 Mn |
| Sep 30, 2024 | -18.50 Mn |
| Jun 30, 2024 | -99.30 Mn |
| Mar 31, 2024 | -79.80 Mn |
| Dec 31, 2023 | -48.60 Mn |
| Sep 30, 2023 | -16.10 Mn |
| Jun 30, 2023 | 25.00 Mn |
| Mar 31, 2023 | 8.00 Mn |
| Dec 31, 2022 | -13.60 Mn |
| Sep 30, 2022 | 60.60 Mn |
| Jun 30, 2022 | 66.40 Mn |